sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÒÆÖ²ÐÔ¹ÇÖ×Áö¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ƥ·ô¹Ç÷À¼¡ÏµÍ³Ä£×Ó > ÒÆÖ²ÐÔ¹ÇÖ×Áö¶¯ÎïÄ£×Ó

ǰÑÔ

¹ÇÖ×Áö(bone tumor)ÊDZ¬·¢ÓÚ¹Ç÷À»òÆäÁ¥Êô×éÖ¯£¨Ñª¹Ü¡¢Éñ¾­¡¢¹ÇËèµÈ£©µÄÖ×Áö£¬Ò»Ñùƽ³£Ô­·¢ÓڹɹÇ×îºó¡¢ëֹǺÍëŹÇÖÜΧ£¬ÔÚÇà´ºÆÚ³¤¹Ç¿ìËÙÉú³¤ºó±»Õï¶Ï³öÀ´£¬µ«ÆäÈ·Çв¡Òò²»Ã÷¡£ÓÉÓÚ¶ñÐÔ¹ÇÖ×ÁöÉú³¤Ñ¸ËÙÓúºó²»¼ÑéæÃüÂʸߣ¬¹ÊÑо¿½ÏΪÆÕ±é¡£¹ÇÖ×Áö¶¯ÎïÄ£×Ó¿É·ÖÎªÒÆÖ²ÐÔÄ£×ӺͻùÒòÐÞÊÎÄ£×Ó¡£ÆäÖУ¬¿ÉÒÆÖ²Ö×ÁöÄ£×Óͨ³£ÓÖ·ÖΪͬÖÖÒìÌåÒÆÖ²ºÍÒìÖÖ¶¯ÎïÒÆÖ²£¬ÒÆÖ²Ö×Áö¿ÉÒÔÊÇÖ×Áö×éÖ¯¿é£¬Ò²¿ÉÒÔÊÇϸ°ûÖê¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó¡¢¼ÒÍÃ

¡¾ÔìÄ£»úÖÆ¡¿£º

ͬÖÖÒìÌåÒÆÖ²ÊÇÔÚͬÖÖ»òͬϵ¶¯ÎïÉíÉÏÒÆÖ²£¬»úÌå¼ä¼´¹©ÌåºÍÊÜÌå¼äµÄ¹²ÐÔ´ó£¬ÈÝÒ×ÔÚ»úÌåÄÚÍ£Áô£¬Éú³¤×ÌÉú£¬ÔÙÏÖÆäÖ×ÁöÀú³Ì¡£Í¨³£Ñ¡ÓÃСÓÚ6ÖܵÄSprague Dawley´óÊ󣨴˽׶δóÊóÃâÒß¹¦Ð§ÉÐδÍêÉÆ£©£¬Ñ¡ÓôóÊó¹ÇѪÁöϸ°ûÖêUMR106¾ÙÐÐͬÖÖÒìÌå¹ÇÄÚÔ­Î»ÒÆÖ²£¬¸Ãϸ°ûÖêÊÇ 20ÊÀ¼Í70ÄêÔÂSprague         Dawley´óÊó¾­·ÅÉäÐÔÁ×ÓÕµ¼»ñµÃµÄÒ»ÖֳɹÇѪÁöϸ°ûÖ꣬åÇÀ´Òѱ»ÓÃÓÚ¹¹½¨¹ÇѪÁöµÄÔ­Î»ÒÆÖ²Ä£×Ó£¬Æä³ÉÁöÂʸߣ¬·Î×ªÒÆÄÜÁ¦Ç¿£¬ÊÇ·Î×ªÒÆÑо¿µÄÀíÏëϸ°ûÖê¡£Ö×Áöϸ°ûÔÚȱ·¦ÓÐÓõÄÃâÒß¼àÊÓÌõ¼þϱ¬·¢ÌÓÒÝÉú³¤£¬¿É»ñµÃ½Ï¸ßµÄÀÖ³ÉÂÊ¡£ÏÖÔڿɹ©Ñ¡ÔñʹÓõÄϸ°ûϵ»òϸ°ûÖê½Ï¶à£¬Ðí¶àϸ°ûϵÔÚÌìϹæÄ£ÂþÑܯձ飬²¢ÇÒÕâЩϸ°ûµÄÉúÎïÑ§ÌØÕ÷ÒѾ­½ÏÁ¿Ã÷È·£¬Ò»Ñùƽ³£¶¼ÓÐÃ÷È·µÄÅä¾°×ÊÁÏ£¬Ê¹Ò»Èº¶¯Îïͬʱ½ÓÖÖͬÑùÁ¿µÄÁöϸ°û£¬Éú³¤ËÙÂÊÒ»Ö£¬¸öÌå²î±ð½ÏС£¬³É»îÂʸߣ¬Ò×ÓÚ¶ÔÕÕÊÓ²ìÕâЩ¶¼ÊDZãÓÚ¿ÆÑÐЧ¹ûÏ໥½ÏÁ¿ºÍ½»Á÷µÄÓÐÀûÒòËØ¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.´óÊó ÌåÍâ×÷Óý´óÊó¹ÇѪÁöϸ°ûϵUMR-106£¬»ñµÃ¶ÔÊýÉúºã¾Ãϸ°û±¸Óá£Ñ¡È¡30~40ÈÕÁäµÄWistar´óÊó£¬êòĵ¸÷°ë£¬ÑÎËáÂȰ·Íª×¢ÉäÒº¼¡ÄÚ×¢ÉäÂé×í(0.1g/kg)£¬µâ¾ÆÏû¶¾ÏÂÖ«£¬ÔÚëÖ¹ÇÉϲ¿¸É÷¿¶ËÄÚ²à»ò¹É¹Ç϶ËÍâ²à×÷ÇпÚ£¬ÊèɢƤÏÂ×é̻֯¶¹ÇÃæºó£¬ÓÃÖ±¾¶1mm¿ËÊÏÕëÇáÈá×êÈë¹ÇËèÇ»£¬ÓÐÏÔ×ŵÄÂä¿Õ¸Ð£¬È»ºóÓÃ12ºÅÊäѪÕëÍ·ÑØ´Ë¿Õб×êÈëËèÇ»£¬ÍÚÈ¡ÆäÖйÇËèºÍ¹ÇËÉÖÊ£¬ÐγÉÒ»ÇãбͨµÀ£¬ÓÃÎÞѪÇåRPMT1640×÷ÓýÒº½«±¸ÓõĹÇѪÁöϸ°ûÏ¡ÊͳÉ5×106/ml£¬Ã¿¸ö¹ÇËèÇ»ÄÚ×¢Éä0.2ml£¬¹ÇÀ¯·â¿Ú£¬ÒÀ´Î·ìºÏ¼¡Ä¤¡¢Æ¤·ô£¬Ïû¶¾Çпںó°üÔú£¬ËÇÑøÊӲ죬4Öܼ´¿ÉÔìÄ£Àֳɡ£

2.¼ÒÍàѡÓÃVX2ϸ°ûÖê×÷ΪÑо¿¹¤¾ß£¬ÏÈÔÚÍúóÖ«¼¡ÈâÄÚ×¢Éäϸ°ûÐüÒº£¬ÖƱ¸ºÉÁöÍã¬3ÖÜÖ×ÁöÉú³¤ÖÁÖ±¾¶Ô¼5cmµÄÖ׿éʱ£¬È¡ÐÂÏʵÄÓãÈâÑùÖ×Áö×éÖ¯¼ôË飬·ÅÈë200~400Ä¿µÄϸ°ûɸÄÚ£¬¼·Ñ¹¹ýÂË£¬²¢ÓÃHanksÒº³åÏ´¡£ÍøÂçϸ°ûÐüÒº£¬ÒÔ1500r/minÀëÐÄ3·ÖÖÓ£¬ÐγɵijÁµíСÇòÔÙ´ÎÐü¸¡ÓÚHanksÒºÖУ¬ÖƳÉ1 ×106/mlµÄÖ×Áöϸ°ûÐüÒººó£¬ÎÞ¾úÌõ¼þÏÂÂé×íʵÑ鶯ÎÓÚÓÒÏ¥ÊàŦ÷ƹÇÏ·½×ÝÐÐÇпªÆ¤·ô³¤Ô¼1cm£¬´¥¼°ëÖ¹ÇÆ½Ì¨£¬18GµÄ¹Ç´©Õë¾­ëֹǽü¶ËÊàÅ¦Ãæ´©´Ì£¬´©´ÌÕëÓëëÖ¹ÇÖ÷¸ÉƽÐУ¬×ª¶¯´©´ÌÕ룬µ±±¬·¢Âä¿Õ¸Ðʱ£¬´©´ÌÕëÍ·¼´½øÈë¹ÇËèÇ»ÄÚ£¬½«´©´ÌÕëËÍÈë2.0~2.5cm£¬Õë¼âλÓÚëֹǹÇËèÇ»ÖÐÉ϶Σ¬×¢Èë0.3mlÖ×Áöϸ°ûÐüÒº£¬°ÎÕ룬·ìºÏƤ·ô¡£

¡¾Ä£×ÓÌØµã¡¿£º

´óÊó½ÓÖÖÁöϸ°û£¬Ö²Èë¹ÇÄÚºó3ÖÜ£¬÷¿¶Ë·ºÆðÅò´ó£¬ÁöÇøÆ¤Ï¿ɼû¸»ºñµÄÓØÇúСѪ¹Ü£»ÇÐÃæ¿É¼ûƤÄÚÖÊÆÆËð¶ÏÁÑ£¬Ö×ÁöÇÖ¼°Èí×éÖ¯£¬Ç»ÄÚÍâµÄÖ×Áö×éÖ¯³ÊÓãÈâ×´£»ÒÆÖ²ºóÖÜΧ£¬÷¿¶ËÇòÐÎÅò´ó£¬Ö׿éÖ±¾¶¿É´ï2~3cm¾Þϸ£¬ÖÊÖлòÉÔÓ²£¬¹ÇƤÖÊÆÆËð¸üÏÔ×Å£¬·ÎÃż°±ßÑØÓÐÉÙÁ¿×ªÒÆÔ¾Þϸ²»µÈ£»ÒÆÖ²ºó6ÖÜ£¬Ö×Áö³Ê¾ÞÇòÐΣ¬ÖÊÉÔÓ²£»ÇÐÃæ¼Ê¹ÇƤÖÊÒÑÏûÊÅ£¬½ö¼ûÖ÷¸É²Ð¶Ë£»Ë«·Î¼û´ó×Ú×ªÒÆÁö£¬¾Þϸ²»µÈ£¬²¿·ÖÁöÔîÈںϣ¬»Ò°×É«£»ÒÆÖ²ºó7ÖÜ£¬ÓÒÏÂÖ«Ö×ÁöÖ±¾¶¿É´ï3~5cm£¬Ë«·ÎÆÕ±é×ªÒÆÔÁöÔîÈںϣ¬Õý³£·Î×éÖ¯½á¹¹»ù±¾ÏûÊÅ¡£Ä£×ÓÊó×ÔÈ»ÉúÑÄÆÚΪ7ÖÜ×óÓÒ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

´óÊóÄ£×ÓÀÖ³ÉÂʽÏÂãÊóºÉÁöÄ£×ÓÂԵͣ¬µ«ÈôÊǽ«½ÓÖÖºó·ºÆðÉú³¤ºÍ×ªÒÆµÄÁöÌå×éÖ¯ÔȽ¬ºóÔÙ½ÓÖÖ£¬ÀÖ³ÉÂʽ«Ìá¸ß¡£ËäȻͬÖÖ¶¯Îï¼äÇãÔþ×÷ÓÃÏà¶Ô½ÏÈõ£¬¿ÉÊDzî±ðÇéÐεĸöÌ壬ÐÄÀí״̬²î±ðºÜ´ó£¬Òò¶øÊʵ±½µµÍÆäÃâÒßÁ¦»ò¸Ä±ä½ÓÖÖ·½·¨£¬Ò²ÄִܵïÔöÌí³ÉÁöµÄЧ¹û¡£¸ÃÄ£×ÓÊÔÑéÖÜÆÚ¶Ì£¬¶¯ÎﱾǮµÍ£¬±ãÓÚËÇÑøÖÎÀí£¬¹Ê±»ÆÕ±éÓ¦Óá£ÍÃÄ£×Óͨ¹ý¾­ëֹǽü¶ËÊàÅ¦Ãæ´©´Ì½«Ö×ÁöݪֲÔÚëÖ¹ÇÖÐÉ϶εĹÇËèÇ»ÄÚ£¬¿É½«¹ÇĤÊܵ½µÄ»úеÐÔËðÉ˼õСµ½×îС£¬ÇÒ´©´Ì¿×¾àÀëÖ×Áöݪֲ²¿Î»Ïà¶Ô½ÏÔ¶£¬Ö×Áö²»Ò×ͨ¹ý¸Ã¿×ÏòÍâÉú³¤¡£

 

²Î¿¼ÎÄÏ×£º

1.ÕÅСÁᣬÃÏ㪷Ç£¬Õų¯êÍ£®¸ÄÁ¼·¨ÍÃVX2¹ÇÖ×ÁöÄ£×ӵIJ¡ÀíѧÓëÓ°Ïñѧ¹Û£®Öйú¹ÇÖ×Áö¹Ç²¡£¬2007,6(2): 89-92

2.Ê©ÐÂé࣬¹ËΪÍû£®ÈËÀ༲²¡¶¯ÎïÄ£×Ó£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2008

3.¹ÜÃ÷Ç¿£¬Ê·Õ¼¾ü£¬ÀîÅô£®¹ÇѪÁöºÉÁöÂãÊóÄ£×ÓÁ½ÖÖ²î±ðÖÆ×÷ÒªÁìµÄ½ÏÁ¿£®ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2008,28(11): 1960-1963

4.Bradgon CR,Jasty M,Muratoglu OK,et al. Third-body wear testing of a highly cross-linked acetahular liner. J Arthroplasty,2005,20 (3):379-385

5.Entz-Werl N,Choquet P,Neuville A,et al. Targeted ape; twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. Transl Oncol, 2010, 3 (6):344-353

6.Garvin K,Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Ort.bop Relat Res, 2005, 437:105-110

7.Jane LF,Peler SM,Monique LH. The expression of the urokmnase plasminogen activator  system in metaslatic murine osteosarcoma:an in vivo mouse model. Clin Cancer Res,2001, 7 (6):1654-1660

8.Walkley CR,Qudsi R,Sankaran VG,et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev, 2008, 22 (12):1662-1676

 

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ƥ·ô¹Ç÷À¼¡ÏµÍ³Ä£×Ó > ÒÆÖ²ÐÔ¹ÇÖ×Áö¶¯ÎïÄ£×Ó
ÒÆÖ²ÐÔ¹ÇÖ×Áö¶¯ÎïÄ£×Ó

ǰÑÔ

¹ÇÖ×Áö(bone tumor)ÊDZ¬·¢ÓÚ¹Ç÷À»òÆäÁ¥Êô×éÖ¯£¨Ñª¹Ü¡¢Éñ¾­¡¢¹ÇËèµÈ£©µÄÖ×Áö£¬Ò»Ñùƽ³£Ô­·¢ÓڹɹÇ×îºó¡¢ëֹǺÍëŹÇÖÜΧ£¬ÔÚÇà´ºÆÚ³¤¹Ç¿ìËÙÉú³¤ºó±»Õï¶Ï³öÀ´£¬µ«ÆäÈ·Çв¡Òò²»Ã÷¡£ÓÉÓÚ¶ñÐÔ¹ÇÖ×ÁöÉú³¤Ñ¸ËÙÓúºó²»¼ÑéæÃüÂʸߣ¬¹ÊÑо¿½ÏΪÆÕ±é¡£¹ÇÖ×Áö¶¯ÎïÄ£×Ó¿É·ÖÎªÒÆÖ²ÐÔÄ£×ӺͻùÒòÐÞÊÎÄ£×Ó¡£ÆäÖУ¬¿ÉÒÆÖ²Ö×ÁöÄ£×Óͨ³£ÓÖ·ÖΪͬÖÖÒìÌåÒÆÖ²ºÍÒìÖÖ¶¯ÎïÒÆÖ²£¬ÒÆÖ²Ö×Áö¿ÉÒÔÊÇÖ×Áö×éÖ¯¿é£¬Ò²¿ÉÒÔÊÇϸ°ûÖê¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó¡¢¼ÒÍÃ

¡¾ÔìÄ£»úÖÆ¡¿£º

ͬÖÖÒìÌåÒÆÖ²ÊÇÔÚͬÖÖ»òͬϵ¶¯ÎïÉíÉÏÒÆÖ²£¬»úÌå¼ä¼´¹©ÌåºÍÊÜÌå¼äµÄ¹²ÐÔ´ó£¬ÈÝÒ×ÔÚ»úÌåÄÚÍ£Áô£¬Éú³¤×ÌÉú£¬ÔÙÏÖÆäÖ×ÁöÀú³Ì¡£Í¨³£Ñ¡ÓÃСÓÚ6ÖܵÄSprague Dawley´óÊ󣨴˽׶δóÊóÃâÒß¹¦Ð§ÉÐδÍêÉÆ£©£¬Ñ¡ÓôóÊó¹ÇѪÁöϸ°ûÖêUMR106¾ÙÐÐͬÖÖÒìÌå¹ÇÄÚÔ­Î»ÒÆÖ²£¬¸Ãϸ°ûÖêÊÇ 20ÊÀ¼Í70ÄêÔÂSprague         Dawley´óÊó¾­·ÅÉäÐÔÁ×ÓÕµ¼»ñµÃµÄÒ»ÖֳɹÇѪÁöϸ°ûÖ꣬åÇÀ´Òѱ»ÓÃÓÚ¹¹½¨¹ÇѪÁöµÄÔ­Î»ÒÆÖ²Ä£×Ó£¬Æä³ÉÁöÂʸߣ¬·Î×ªÒÆÄÜÁ¦Ç¿£¬ÊÇ·Î×ªÒÆÑо¿µÄÀíÏëϸ°ûÖê¡£Ö×Áöϸ°ûÔÚȱ·¦ÓÐÓõÄÃâÒß¼àÊÓÌõ¼þϱ¬·¢ÌÓÒÝÉú³¤£¬¿É»ñµÃ½Ï¸ßµÄÀÖ³ÉÂÊ¡£ÏÖÔڿɹ©Ñ¡ÔñʹÓõÄϸ°ûϵ»òϸ°ûÖê½Ï¶à£¬Ðí¶àϸ°ûϵÔÚÌìϹæÄ£ÂþÑܯձ飬²¢ÇÒÕâЩϸ°ûµÄÉúÎïÑ§ÌØÕ÷ÒѾ­½ÏÁ¿Ã÷È·£¬Ò»Ñùƽ³£¶¼ÓÐÃ÷È·µÄÅä¾°×ÊÁÏ£¬Ê¹Ò»Èº¶¯Îïͬʱ½ÓÖÖͬÑùÁ¿µÄÁöϸ°û£¬Éú³¤ËÙÂÊÒ»Ö£¬¸öÌå²î±ð½ÏС£¬³É»îÂʸߣ¬Ò×ÓÚ¶ÔÕÕÊÓ²ìÕâЩ¶¼ÊDZãÓÚ¿ÆÑÐЧ¹ûÏ໥½ÏÁ¿ºÍ½»Á÷µÄÓÐÀûÒòËØ¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.´óÊó ÌåÍâ×÷Óý´óÊó¹ÇѪÁöϸ°ûϵUMR-106£¬»ñµÃ¶ÔÊýÉúºã¾Ãϸ°û±¸Óá£Ñ¡È¡30~40ÈÕÁäµÄWistar´óÊó£¬êòĵ¸÷°ë£¬ÑÎËáÂȰ·Íª×¢ÉäÒº¼¡ÄÚ×¢ÉäÂé×í(0.1g/kg)£¬µâ¾ÆÏû¶¾ÏÂÖ«£¬ÔÚëÖ¹ÇÉϲ¿¸É÷¿¶ËÄÚ²à»ò¹É¹Ç϶ËÍâ²à×÷ÇпÚ£¬ÊèɢƤÏÂ×é̻֯¶¹ÇÃæºó£¬ÓÃÖ±¾¶1mm¿ËÊÏÕëÇáÈá×êÈë¹ÇËèÇ»£¬ÓÐÏÔ×ŵÄÂä¿Õ¸Ð£¬È»ºóÓÃ12ºÅÊäѪÕëÍ·ÑØ´Ë¿Õб×êÈëËèÇ»£¬ÍÚÈ¡ÆäÖйÇËèºÍ¹ÇËÉÖÊ£¬ÐγÉÒ»ÇãбͨµÀ£¬ÓÃÎÞѪÇåRPMT1640×÷ÓýÒº½«±¸ÓõĹÇѪÁöϸ°ûÏ¡ÊͳÉ5×106/ml£¬Ã¿¸ö¹ÇËèÇ»ÄÚ×¢Éä0.2ml£¬¹ÇÀ¯·â¿Ú£¬ÒÀ´Î·ìºÏ¼¡Ä¤¡¢Æ¤·ô£¬Ïû¶¾Çпںó°üÔú£¬ËÇÑøÊӲ죬4Öܼ´¿ÉÔìÄ£Àֳɡ£

2.¼ÒÍàѡÓÃVX2ϸ°ûÖê×÷ΪÑо¿¹¤¾ß£¬ÏÈÔÚÍúóÖ«¼¡ÈâÄÚ×¢Éäϸ°ûÐüÒº£¬ÖƱ¸ºÉÁöÍã¬3ÖÜÖ×ÁöÉú³¤ÖÁÖ±¾¶Ô¼5cmµÄÖ׿éʱ£¬È¡ÐÂÏʵÄÓãÈâÑùÖ×Áö×éÖ¯¼ôË飬·ÅÈë200~400Ä¿µÄϸ°ûɸÄÚ£¬¼·Ñ¹¹ýÂË£¬²¢ÓÃHanksÒº³åÏ´¡£ÍøÂçϸ°ûÐüÒº£¬ÒÔ1500r/minÀëÐÄ3·ÖÖÓ£¬ÐγɵijÁµíСÇòÔÙ´ÎÐü¸¡ÓÚHanksÒºÖУ¬ÖƳÉ1 ×106/mlµÄÖ×Áöϸ°ûÐüÒººó£¬ÎÞ¾úÌõ¼þÏÂÂé×íʵÑ鶯ÎÓÚÓÒÏ¥ÊàŦ÷ƹÇÏ·½×ÝÐÐÇпªÆ¤·ô³¤Ô¼1cm£¬´¥¼°ëÖ¹ÇÆ½Ì¨£¬18GµÄ¹Ç´©Õë¾­ëֹǽü¶ËÊàÅ¦Ãæ´©´Ì£¬´©´ÌÕëÓëëÖ¹ÇÖ÷¸ÉƽÐУ¬×ª¶¯´©´ÌÕ룬µ±±¬·¢Âä¿Õ¸Ðʱ£¬´©´ÌÕëÍ·¼´½øÈë¹ÇËèÇ»ÄÚ£¬½«´©´ÌÕëËÍÈë2.0~2.5cm£¬Õë¼âλÓÚëֹǹÇËèÇ»ÖÐÉ϶Σ¬×¢Èë0.3mlÖ×Áöϸ°ûÐüÒº£¬°ÎÕ룬·ìºÏƤ·ô¡£

¡¾Ä£×ÓÌØµã¡¿£º

´óÊó½ÓÖÖÁöϸ°û£¬Ö²Èë¹ÇÄÚºó3ÖÜ£¬÷¿¶Ë·ºÆðÅò´ó£¬ÁöÇøÆ¤Ï¿ɼû¸»ºñµÄÓØÇúСѪ¹Ü£»ÇÐÃæ¿É¼ûƤÄÚÖÊÆÆËð¶ÏÁÑ£¬Ö×ÁöÇÖ¼°Èí×éÖ¯£¬Ç»ÄÚÍâµÄÖ×Áö×éÖ¯³ÊÓãÈâ×´£»ÒÆÖ²ºóÖÜΧ£¬÷¿¶ËÇòÐÎÅò´ó£¬Ö׿éÖ±¾¶¿É´ï2~3cm¾Þϸ£¬ÖÊÖлòÉÔÓ²£¬¹ÇƤÖÊÆÆËð¸üÏÔ×Å£¬·ÎÃż°±ßÑØÓÐÉÙÁ¿×ªÒÆÔ¾Þϸ²»µÈ£»ÒÆÖ²ºó6ÖÜ£¬Ö×Áö³Ê¾ÞÇòÐΣ¬ÖÊÉÔÓ²£»ÇÐÃæ¼Ê¹ÇƤÖÊÒÑÏûÊÅ£¬½ö¼ûÖ÷¸É²Ð¶Ë£»Ë«·Î¼û´ó×Ú×ªÒÆÁö£¬¾Þϸ²»µÈ£¬²¿·ÖÁöÔîÈںϣ¬»Ò°×É«£»ÒÆÖ²ºó7ÖÜ£¬ÓÒÏÂÖ«Ö×ÁöÖ±¾¶¿É´ï3~5cm£¬Ë«·ÎÆÕ±é×ªÒÆÔÁöÔîÈںϣ¬Õý³£·Î×éÖ¯½á¹¹»ù±¾ÏûÊÅ¡£Ä£×ÓÊó×ÔÈ»ÉúÑÄÆÚΪ7ÖÜ×óÓÒ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

´óÊóÄ£×ÓÀÖ³ÉÂʽÏÂãÊóºÉÁöÄ£×ÓÂԵͣ¬µ«ÈôÊǽ«½ÓÖÖºó·ºÆðÉú³¤ºÍ×ªÒÆµÄÁöÌå×éÖ¯ÔȽ¬ºóÔÙ½ÓÖÖ£¬ÀÖ³ÉÂʽ«Ìá¸ß¡£ËäȻͬÖÖ¶¯Îï¼äÇãÔþ×÷ÓÃÏà¶Ô½ÏÈõ£¬¿ÉÊDzî±ðÇéÐεĸöÌ壬ÐÄÀí״̬²î±ðºÜ´ó£¬Òò¶øÊʵ±½µµÍÆäÃâÒßÁ¦»ò¸Ä±ä½ÓÖÖ·½·¨£¬Ò²ÄִܵïÔöÌí³ÉÁöµÄЧ¹û¡£¸ÃÄ£×ÓÊÔÑéÖÜÆÚ¶Ì£¬¶¯ÎﱾǮµÍ£¬±ãÓÚËÇÑøÖÎÀí£¬¹Ê±»ÆÕ±éÓ¦Óá£ÍÃÄ£×Óͨ¹ý¾­ëֹǽü¶ËÊàÅ¦Ãæ´©´Ì½«Ö×ÁöݪֲÔÚëÖ¹ÇÖÐÉ϶εĹÇËèÇ»ÄÚ£¬¿É½«¹ÇĤÊܵ½µÄ»úеÐÔËðÉ˼õСµ½×îС£¬ÇÒ´©´Ì¿×¾àÀëÖ×Áöݪֲ²¿Î»Ïà¶Ô½ÏÔ¶£¬Ö×Áö²»Ò×ͨ¹ý¸Ã¿×ÏòÍâÉú³¤¡£

 

²Î¿¼ÎÄÏ×£º

1.ÕÅСÁᣬÃÏ㪷Ç£¬Õų¯êÍ£®¸ÄÁ¼·¨ÍÃVX2¹ÇÖ×ÁöÄ£×ӵIJ¡ÀíѧÓëÓ°Ïñѧ¹Û£®Öйú¹ÇÖ×Áö¹Ç²¡£¬2007,6(2): 89-92

2.Ê©ÐÂé࣬¹ËΪÍû£®ÈËÀ༲²¡¶¯ÎïÄ£×Ó£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2008

3.¹ÜÃ÷Ç¿£¬Ê·Õ¼¾ü£¬ÀîÅô£®¹ÇѪÁöºÉÁöÂãÊóÄ£×ÓÁ½ÖÖ²î±ðÖÆ×÷ÒªÁìµÄ½ÏÁ¿£®ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2008,28(11): 1960-1963

4.Bradgon CR,Jasty M,Muratoglu OK,et al. Third-body wear testing of a highly cross-linked acetahular liner. J Arthroplasty,2005,20 (3):379-385

5.Entz-Werl N,Choquet P,Neuville A,et al. Targeted ape; twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. Transl Oncol, 2010, 3 (6):344-353

6.Garvin K,Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Ort.bop Relat Res, 2005, 437:105-110

7.Jane LF,Peler SM,Monique LH. The expression of the urokmnase plasminogen activator  system in metaslatic murine osteosarcoma:an in vivo mouse model. Clin Cancer Res,2001, 7 (6):1654-1660

8.Walkley CR,Qudsi R,Sankaran VG,et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev, 2008, 22 (12):1662-1676

 

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿